title: A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.
authors.affiliation: Astellas Global Medical Affairs, Northbrook, IL; Department of Urology, Loyola University School of Medicine, Maywood, IL. Electronic address: gabriel.haas@astellas.com.
authors.forename: Gabriel P
authors.initials: GP
authors.lastname: Haas
authors.affiliation: Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
authors.forename: Howard I
authors.initials: HI
authors.lastname: Scher
mesh_terms: D001688:Biological Products / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D014481:United States; D014486:United States Food and Drug Administration; D014571:Urologic Neoplasms / Q000188:drug therapy; D014572:Urology / Q000379:methods*
chemical_list: D001688:Biological Products; D014408:Biomarkers, Tumor